GlaxoSmithKline PLC plans sharp changes to its emerging market business model with an eye on long-term profitable growth and being “better” at rolling out innovations in the region, its new CEO Emma Walmsley said.
"We are focusing our commercial efforts on driving an improved performance in the US which is, without doubt, the priority market but the biggest change geographically in fact is going to be about being more competitive in our emerging markets business," she said at the second